Patents by Inventor Lori Jean VAN ORDEN

Lori Jean VAN ORDEN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • JAK inhibitors containing a 4-membered heterocyclic amide
    Patent number: 11878977
    Abstract: The invention provides compounds of formula (I): which contain a 4-membered heterocyclic amide, where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: August 10, 2022
    Date of Patent: January 23, 2024
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Paul R. Fatheree, Gary E. L. Brandt, Cameron Smith, Steven D. E. Sullivan, Lori Jean Van Orden, Melanie A. Kleinschek, Glenn D. Crater
  • JAK kinase inhibitor compounds for treatment of respiratory disease
    Patent number: 11718616
    Abstract: The invention provides compounds of formula (I): wherein X is and the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: March 7, 2022
    Date of Patent: August 8, 2023
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Paul R. Fatheree, John R. Jacobsen, Anne-Marie Beausoleil, Gary E. L. Brandt, Melissa Fleury, Lan Jiang, Cameron Smith, Steven D. E. Sullivan, Lori Jean Van Orden, Pierre-Jean Colson, Gene Timothy Fass, Miroslav Rapta, Noah Benjamin, Marta Dabros, Venkat R. Thalladi
  • Fused imidazo-piperidine JAK inhibitors
    Patent number: 11667637
    Abstract: The invention provides compounds of formula (I): where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: January 14, 2022
    Date of Patent: June 6, 2023
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Paul R. Fatheree, Gary E. L. Brandt, Cameron Smith, Steven D. E. Sullivan, Lori Jean Van Orden, Melanie A. Kleinschek, Glenn D. Crater
  • JAK INHIBITORS CONTAINING A 4-MEMBERED HETEROCYCLIC AMIDE
    Publication number: 20230063643
    Abstract: The invention provides compounds of formula (I): which contain a 4-membered heterocyclic amide, where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: August 10, 2022
    Publication date: March 2, 2023
    Inventors: PAUL R. FATHEREE, GARY E.L. BRANDT, CAMERON SMITH, STEVEN D.E. SULLIVAN, LORI JEAN VAN ORDEN, MELANIE A. KLEINSCHEK, GLENN D. CRATER
  • JAK KINASE INHIBITOR COMPOUNDS FOR TREATMENT OF RESPIRATORY DISEASE
    Publication number: 20220306624
    Abstract: The invention provides compounds of formula (I): wherein X is and the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: March 7, 2022
    Publication date: September 29, 2022
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Paul R. Fatheree, John R. Jacobsen, Anne-Marie Beausoleil, Gary E.L. Brandt, Melissa Fleury, Lan Jiang, Cameron Smith, Steven D.E. Sullivan, Lori Jean Van Orden, Pierre-Jean Colson, Gene Timothy Fass, Miroslav Rapta, Noah Benjamin, Marta Dabros, Venkat R. Thalladi
  • JAK inhibitors containing a 4-membered heterocyclic amide
    Patent number: 11453668
    Abstract: The invention provides compounds of formula (I): which contain a 4-membered heterocyclic amide, where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: February 12, 2021
    Date of Patent: September 27, 2022
    Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Paul R. Fatheree, Gary E. L. Brandt, Cameron Smith, Steven D. E. Sullivan, Lori Jean Van Orden
  • FUSED IMIDAZO-PIPERIDINE JAK INHIBITORS
    Publication number: 20220289737
    Abstract: The invention provides compounds of formula (I): where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: January 14, 2022
    Publication date: September 15, 2022
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Paul R. Fatheree, Gary E. L. Brandt, Cameron Smith, Steven D. E. Sullivan, Lori Jean Van Orden, Melanie A. Kleinschek, Glenn D. Crater
  • JAK kinase inhibitor compounds for treatment of respiratory disease
    Patent number: 11299492
    Abstract: The invention provides compounds of formula (I): wherein X is and the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: January 5, 2021
    Date of Patent: April 12, 2022
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Paul R. Fatheree, John R. Jacobsen, Gary E. L. Brandt, Melissa Fleury, Lan Jiang, Cameron Smith, Steven D. E. Sullivan, Lori Jean Van Orden, Anne-Marie Beausoleil
  • Fused imidazo-piperidine JAK inhibitors
    Patent number: 11254669
    Abstract: The invention provides compounds of formula (I): where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: November 11, 2019
    Date of Patent: February 22, 2022
    Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Paul R. Fatheree, Gary E. L. Brandt, Cameron Smith, Steven D. E. Sullivan, Lori Jean Van Orden
  • JAK INHIBITORS CONTAINING A 4-MEMBERED HETEROCYCLIC AMIDE
    Publication number: 20210269436
    Abstract: The invention provides compounds of formula (I): which contain a 4-membered heterocyclic amide, where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: February 12, 2021
    Publication date: September 2, 2021
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: PAUL R. FATHEREE, GARY E.L. BRANDT, CAMERON SMITH, STEVEN D.E. SULLIVAN, LORI JEAN VAN ORDEN
  • JAK KINASE INHIBITOR COMPOUNDS FOR TREATMENT OF RESPIRATORY DISEASE
    Publication number: 20210130351
    Abstract: The invention provides compounds of formula (I): wherein X is and the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: January 5, 2021
    Publication date: May 6, 2021
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Paul R. Fatheree, John R. Jacobsen, Gary E.L. Brandt, Melissa Fleury, Lan Jiang, Cameron Smith, Steven D.E. Sullivan, Lori Jean Van Orden, Anne-Marie Beausoleil
  • JAK inhibitors containing a 4-membered heterocyclic amide
    Patent number: 10954237
    Abstract: The invention provides compounds of formula (I): which contain a 4-membered heterocyclic amide, where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: December 3, 2019
    Date of Patent: March 23, 2021
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Paul R. Fatheree, Gary E. L. Brandt, Cameron Smith, Steven D. E. Sullivan, Lori Jean Van Orden
  • JAK INHIBITORS CONTAINING A 4-MEMBERED HETEROCYCLIC AMIDE
    Publication number: 20200216447
    Abstract: The invention provides compounds of formula (I): which contain a 4-membered heterocyclic amide, where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: December 3, 2019
    Publication date: July 9, 2020
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: PAUL R. FATHEREE, GARY E.L. BRANDT, CAMERON SMITH, STEVEN D.E. SULLIVAN, LORI JEAN VAN ORDEN
  • FUSED IMIDAZO-PIPERIDINE JAK INHIBITORS
    Publication number: 20200181141
    Abstract: The invention provides compounds of formula (I): where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: November 11, 2019
    Publication date: June 11, 2020
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: PAUL R. FATHEREE, GARY E.L. BRANDT, CAMERON SMITH, STEVEN D.E. SULLIVAN, LORI JEAN VAN ORDEN
  • JAK inhibitors containing a 4-membered heterocyclic amide
    Patent number: 10550118
    Abstract: The invention provides compounds of formula (I): which contain a 4-membered heterocyclic amide, where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: July 15, 2019
    Date of Patent: February 4, 2020
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Paul R. Fatheree, Gary E. L. Brandt, Cameron Smith, Steven D. E. Sullivan, Lori Jean Van Orden, Melanie A. Kleinschek, Glenn D. Crater
  • JAK kinase inhibitor compounds for treatment of respiratory disease
    Patent number: 10526330
    Abstract: The invention provides compounds of formula (I): wherein X is and the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: December 10, 2018
    Date of Patent: January 7, 2020
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Paul R. Fatheree, John R. Jacobsen, Gary E. L. Brandt, Melissa Fleury, Lan Jiang, Cameron Smith, Steven D. E. Sullivan, Lori Jean Van Orden, Anne-Marie Beausoleil
  • Fused imidazo-piperidine JAK inhibitors
    Patent number: 10519153
    Abstract: The invention provides compounds of formula (I): where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: December 31, 2019
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Paul R. Fatheree, Gary E. L. Brandt, Cameron Smith, Steven D. E. Sullivan, Lori Jean Van Orden, Melanie A. Kleinschek, Glenn D. Crater
  • JAK INHIBITORS CONTAINING A 4-MEMBERED HETEROCYCLIC AMIDE
    Publication number: 20190337945
    Abstract: The invention provides compounds of formula (I): which contain a 4-membered heterocyclic amide, where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: July 15, 2019
    Publication date: November 7, 2019
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Paul R. FATHEREE, Gary E.L. Brandt, Cameron Smith, Steven D.E. Sullivan, Lori Jean Van Orden, Melanie A. Kleinschek, Glenn D. Crater
  • JAK inhibitors containing a 4-membered heterocyclic amide
    Patent number: 10392386
    Abstract: The invention provides compounds of formula (I): which contain a 4-membered heterocyclic amide, where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: December 17, 2018
    Date of Patent: August 27, 2019
    Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Paul R. Fatheree, Gary E. L. Brandt, Cameron Smith, Steven D. E. Sullivan, Lori Jean Van Orden, Melanie A. Kleinschek, Glenn D. Crater
  • FUSED IMIDAZO-PIPERIDINE JAK INHIBITORS
    Publication number: 20190127371
    Abstract: The invention provides compounds of formula (I): where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: December 19, 2018
    Publication date: May 2, 2019
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: PAUL R. FATHEREE, GARY E.L. BRANDT, CAMERON SMITH, STEVEN D.E. SULLIVAN, LORI JEAN VAN ORDEN, MELANIE A. KLEINSCHEK, GLENN D. CRATER